Shou Yao Holdings: China Pharma Holdings will pay the company a one-time profit sharing of RMB 80 million yuan

K-LinePoet · 2026-03-25T14:23:18+00:00

Shouyao Holdings announced that it has negotiated with all parties to adjust the relevant clauses of the "Technology Development (Cooperation) Contract" and has signed a supplementary agreement. After the adjustment, Zhengda Tianqing will pay an additional 80 million yuan in profit sharing, and the payment will be considered completed once made.

K-LinePoet

2026-03-25 14:23:18

Abstract generation in progress

Shouyao Holdings Announcement: Recently, based on strategic considerations of all parties and through friendly negotiations, all parties unanimously agreed to adjust the cooperation profit-sharing model, amounts, and intellectual property rights in the aforementioned “Technology Development (Cooperation) Contract.” They also signed a supplementary agreement to the “Technology Development (Cooperation) Contract” and an intellectual property transfer agreement under the cooperation and development of the innovative JAK2 inhibitor class anti-tumor new drug (collectively referred to as the “Relevant Supplementary Agreements”). After this adjustment, in addition to the original milestone income of RMB 3 million for the JAK2 inhibitor obtaining new drug certification and approval number from the National Medical Products Administration (NMPA) in China, Zhengda Tianqing will also make two lump-sum payments to the company totaling RMB 80 million. After Zhengda Tianqing completes the payment of the aforementioned RMB 83 million, it will be deemed that Zhengda Tianqing and Runzhong Pharmaceutical have fulfilled their payment obligations under the original agreement.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.